

BCBSMT HEDIS® 2013 COMPARISON REPORT - Managed Care

EFFECTIVENESS OF CARE MEASURES

BCBSMT 2011

BCBSMT 2012

BCBSMT 2013

2012 QC National

2013 QC National

| | Num | Denom | | Num | Denom | % change | Num | Denom | % change | | | | |
|--|---------------|-------|--------------|-----|-------|----------|---------------|-------|----------|--------|---------|--------|--------|
| Childhood Immunization | n=71 | | n=51 | | | | n=31 | | | | | | |
| DTaP | 59 | 71 | 83.10% | 43 | 51 | 84.31% | 1.46% | 26 | 31 | 83.87% | -0.52% | 86.50% | 87.20% |
| Hib | 66 | 71 | 92.96% | 46 | 51 | 90.20% | -2.97% | 30 | 31 | 96.77% | 7.29% | 94.10% | 94.30% |
| IPV | 68 | 71 | 95.77% | 45 | 51 | 88.24% | -7.86% | 30 | 31 | 96.77% | 9.67% | 92.40% | 92.80% |
| PCV | 61 | 71 | 85.92% | 43 | 51 | 84.31% | -1.87% | 27 | 31 | 87.10% | 3.31% | 87.00% | 86.70% |
| HepB | 67 | 71 | 94.37% | 45 | 51 | 88.24% | -6.50% | 30 | 31 | 96.77% | 9.67% | 87.90% | 89.20% |
| MMR | 66 | 71 | 92.96% | 48 | 51 | 94.12% | 1.25% | 29 | 31 | 93.55% | -0.61% | 91.50% | 91.80% |
| VZV | 62 | 71 | 87.32% | 44 | 51 | 86.27% | -1.20% | 29 | 31 | 93.55% | 8.44% | 91.30% | 91.60% |
| HepA^ | 27 | 71 | 38.03% | 21 | 51 | 41.18% | 8.28% | 28 | 31 | 90.32% | 119.34% | 39.00% | 65.50% |
| Rotavirus | 44 | 71 | 61.97% | 39 | 51 | 76.47% | 23.40% | 21 | 31 | 67.74% | -11.41% | 75.10% | 76.70% |
| Influenza | 39 | 71 | 54.93% | 25 | 51 | 49.02% | -10.76% | 20 | 31 | 64.52% | 31.61% | 61.10% | 63.30% |
| Combo-1 | 57 | 71 | 80.28% | 41 | 51 | 80.39% | 0.14% | 25 | 31 | 80.65% | 0.32% | na | na |
| Combo-2 | 56 | 71 | 78.87% | 39 | 51 | 76.47% | -3.04% | 25 | 31 | 80.65% | 5.46% | 78.00% | 79.70% |
| Combo-3 | 53 | 71 | 74.65% | 38 | 51 | 74.51% | -0.19% | 25 | 31 | 80.65% | 8.23% | 75.70% | 76.80% |
| Combo-4 ^ | 23 | 71 | 32.39% | 16 | 51 | 31.37% | -3.15% | 23 | 31 | 74.19% | 136.51% | na | na |
| Combo-5 | 38 | 71 | 53.52% | 34 | 51 | 66.67% | 24.57% | 18 | 31 | 58.06% | -12.91% | na | na |
| Combo-6 | 35 | 71 | 49.30% | 22 | 51 | 43.14% | -12.49% | 17 | 31 | 54.84% | 27.12% | na | na |
| Combo-7 ^ | 20 | 71 | 28.17% | 15 | 51 | 29.41% | 4.40% | 17 | 31 | 54.84% | 86.46% | na | na |
| Combo-8 ^ | 15 | 71 | 21.13% | 10 | 51 | 19.61% | -7.19% | 16 | 31 | 51.61% | 163.20% | na | na |
| Combo-9 | 25 | 71 | 35.21% | 21 | 51 | 41.18% | 16.96% | 12 | 31 | 38.71% | -6.00% | na | na |
| Combo-10 ^ | 12 | 71 | 16.90% | 10 | 51 | 19.61% | 16.04% | 11 | 31 | 35.48% | 80.95% | 22.90% | 37.90% |
| Adolescent Immunizations | n=110 | | n=65 | | | | n=55 | | | | | | |
| Meningococcal (MCV) | 53 | 110 | 48.18% | 39 | 65 | 60.00% | 24.53% | 30 | 55 | 55.45% | -7.58% | 61.90% | 66.00% |
| Tdap/Td | 93 | 110 | 84.55% | 54 | 65 | 83.08% | -1.74% | 44 | 55 | 80.00% | -3.71% | 77.00% | 79.20% |
| Combo-1 | 53 | 110 | 48.18% | 38 | 65 | 58.46% | 21.34% | 29 | 55 | 52.73% | -9.80% | 59.40% | 63.70% |
| HPV Vaccine for Female Adolescents | na | | n=28 | | | | n=31 | | | | | | |
| | na | na | na | 8 | 28 | 28.57% | na | 6 | 31 | 19.35% | -32.25% | na | na |
| Appropriate Tx for Children w/ URI | n=126 | | n=114 | | | | n=53 | | | | | | |
| | 111 | 126 | 88.10% | 93 | 114 | 81.58% | -7.40% | 44 | 53 | 83.02% | 1.76% | 83.90% | 84.00% |
| Appropriate Testing for Children w/ Pharyngitis | n=107 | | n=116 | | | | n=52 | | | | | | |
| | 81 | 107 | 75.70% | 89 | 116 | 76.72% | 1.35% | 32 | 52 | 61.54% | -19.79% | 80.20% | 80.20% |
| Avoidance of Antibiotic Tx for Adults w/ Acute Bronchitis | n=122 | | n=70 | | | | n=66 | | | | | | |
| | 24 | 122 | 19.67% | 7 | 70 | 10.00% | -49.16% | 11 | 66 | 16.67% | 66.70% | 23.50% | 24.60% |
| Colorectal Cancer Screening | n=2105 | | n=601 | | | | n=1153 | | | | | | |
| | 1190 | 2105 | 56.53% | 303 | 601 | 50.42% | -10.81% | 657 | 1153 | 56.98% | 13.01% | 62.40% | 63.30% |

EFFECTIVENESS OF CARE MEASURES
BCBSMT 2011
BCBSMT 2012
BCBSMT 2013
2012 QC National
2013 QC National

| | Num | Denom | | Num | Denom | % change | Num | Denom | % change | | | | |
|---|------|-------|---------------|-----|-------|--------------|---------|-------|--------------|---------|---------|--------|--------|
| Breast Cancer Screening | | | n=1633 | | | n=486 | | | n=865 | | | | |
| | 1182 | 1633 | 72.38% | 328 | 486 | 67.49% | -6.76% | 652 | 865 | 75.38% | 11.68% | 70.50% | 70.30% |
| Cervical Cancer Screening | | | n=2055 | | | n=644 | | | n=982 | | | | |
| | 1608 | 2055 | 78.25% | 501 | 644 | 77.80% | -0.58% | 766 | 982 | 78.00% | 0.26% | 76.50% | 75.50% |
| Persistence of Beta Blocker Treatment after Heart Attack | | | n=7 | | | n=2 | | | n=5 | | | | |
| | 6 | 7 | 85.71% | 2 | 2 | 100.00% | 16.67% | 5 | 5 | 100.00% | 0.00% | 81.30% | 83.90% |
| Cholesterol Management for Patients w/ Cardiovascular Conditions | | | n=75 | | | n=26 | | | n=37 | | | | |
| LDL-screening | 70 | 75 | 93.33% | 24 | 26 | 92.31% | -1.09% | 35 | 37 | 94.59% | 2.47% | 88.10% | 88.30% |
| LDL-C level < 130 mg/dL | 66 | 75 | 88.00% | 22 | 26 | 84.62% | -3.84% | 32 | 37 | 86.49% | 2.21% | na | na |
| LDL-C level < 100 mg/dL | 52 | 75 | 69.33% | 15 | 26 | 57.69% | -16.79% | 27 | 37 | 72.97% | 26.49% | 59.80% | 59.90% |
| Comprehensive Diabetes Care | | | n=271 | | | n=82 | | | n=152 | | | | |
| HbA1c Tested | 255 | 271 | 94.10% | 75 | 82 | 91.46% | -2.81% | 146 | 152 | 96.05% | 5.02% | 90.00% | 90.10% |
| Poor HbA1c Control >9.0% * | 42 | 271 | 15.50% | 17 | 82 | 20.73% | 33.74% | 20 | 152 | 13.16% | -36.53% | 28.30% | 28.50% |
| HbA1c < 8.0% | 198 | 271 | 73.06% | 57 | 82 | 69.51% | -4.86% | 115 | 152 | 75.66% | 8.84% | 61.20% | 61.30% |
| HbA1c < 7.0% ** | 98 | 199 | 49.25% | 29 | 61 | 47.54% | -3.47% | 56 | 105 | 53.33% | 12.19% | 42.20% | 43.20% |
| Eye Exam | 163 | 271 | 60.15% | 50 | 82 | 60.98% | 1.38% | 93 | 152 | 61.18% | 0.33% | 56.90% | 56.80% |
| LDL Screening | 222 | 271 | 81.92% | 67 | 82 | 81.71% | -0.26% | 134 | 152 | 88.16% | 7.89% | 85.30% | 85.40% |
| LDL Level < 130 mg/dL | 177 | 271 | 65.31% | 59 | 82 | 71.95% | 10.17% | 110 | 152 | 72.37% | 0.58% | na | na |
| LDL Level < 100 mg/dL | 123 | 271 | 45.39% | 37 | 82 | 45.12% | -0.59% | 78 | 152 | 51.32% | 13.73% | 48.10% | 48.40% |
| Nephropathy Monitored | 239 | 271 | 88.19% | 75 | 82 | 91.46% | 3.71% | 140 | 152 | 92.11% | 0.71% | 83.80% | 84.30% |
| Blood Pressure < 140/80 mmHg | 134 | 271 | 49.45% | 34 | 82 | 41.46% | -16.16% | 71 | 152 | 46.71% | 12.66% | 44.20% | 44.30% |
| Blood Pressure < 140/90 mmHg | 193 | 271 | 71.22% | 63 | 82 | 76.83% | 7.88% | 111 | 152 | 73.03% | -4.95% | 65.80% | 66.50% |
| Follow-up for Mental Illness | | | n=17 | | | n=11 | | | n=14 | | | | |
| 7 days | 13 | 17 | 76.47% | 5 | 11 | 45.45% | -40.56% | 6 | 14 | 42.86% | -5.70% | 58.90% | 57.90% |
| 30 days | 16 | 17 | 94.12% | 9 | 11 | 81.82% | -13.07% | 11 | 14 | 78.57% | -3.97% | 76.50% | 76.00% |
| Antidepressant Medication Management | | | n=66 | | | n=50 | | | n=38 | | | | |
| Effective Acute Phase Tx | 41 | 66 | 62.12% | 33 | 50 | 66.00% | 6.25% | 27 | 38 | 71.05% | 7.66% | 65.60% | 69.10% |
| Effective Continuation Phase TX | 31 | 66 | 46.97% | 23 | 50 | 46.00% | -2.07% | 21 | 38 | 55.26% | 20.14% | 49.40% | 53.60% |
| Follow-Up for Children Prescribed ADHD Medication | | | n=21 | | | n=9 | | | n=20 | | | | |
| Initiation Phase Visit | 5 | 21 | 23.81% | 5 | 9 | 55.56% | 133.35% | 4 | 20 | 20.00% | -64.00% | 39.40% | 38.60% |
| Use of Appropriate Medications for People with Asthma*** | | | n=78 | | | n=26 | | | n=68 | | | | |
| Ages 5-11 | 10 | 10 | 100.00% | 3 | 4 | 75.00% | -25.00% | 2 | 3 | 66.67% | -11.11% | 96.00% | 95.50% |
| Ages 12-18 | 13 | 13 | 100.00% | 1 | 1 | 100.00% | 0.00% | 2 | 4 | 50.00% | -50.00% | 92.70% | 92.20% |
| Ages 19-50 | 51 | 55 | 92.73% | 11 | 12 | 91.67% | -1.14% | 12 | 23 | 52.17% | -43.09% | 89.10% | 88.20% |

EFFECTIVENESS OF CARE MEASURES
BCBSMT 2011
BCBSMT 2012
BCBSMT 2013
2012 QC National
2013 QC National

| | Num | Denom | | Num | Denom | | % change | Num | Denom | | % change | | |
|--|-----|-------|---------------|--------------|-------|---------|----------|--------------|-------|---------|----------|--------|--------|
| Ages 51-64 | na | na | na | 8 | 9 | 88.89% | na | 15 | 19 | 78.95% | -11.19% | 93.20% | 92.40% |
| Combined *** | 74 | 78 | 94.87% | 23 | 26 | 88.46% | -6.76% | 31 | 49 | 63.27% | -28.48% | 91.90% | 91.20% |
| Use of Spirometry in the Assessment & Diagnoses of COPD | | | n=27 | n=25 | | | | n=29 | | | | | |
| | 7 | 27 | 25.93% | 10 | 25 | 40.00% | 54.26% | 17 | 29 | 58.62% | 46.55% | 42.90% | 43.50% |
| Pharmacotherapy Management of COPD Exacerbation | | | n=4 | n=6 | | | | n=2 | | | | | |
| Bronchodilator | 4 | 4 | 100.00% | 5 | 6 | 83.33% | -16.67% | 2 | 2 | 100.00% | 20.00% | 79.90% | 80.80% |
| Systemic Corticosteroid | 4 | 4 | 100.00% | 5 | 6 | 83.33% | -16.67% | 2 | 2 | 100.00% | 20.00% | 71.30% | 73.50% |
| Chlamydia Screening | | | n=315 | n=98 | | | | n=135 | | | | | |
| Ages 16-20 | 57 | 141 | 40.43% | 14 | 41 | 34.15% | -15.53% | 17 | 57 | 29.82% | -12.67% | 41.50% | 41.10% |
| Ages 21-24 | 65 | 174 | 37.36% | 22 | 57 | 38.60% | 3.32% | 33 | 78 | 42.31% | 9.61% | 48.40% | 49.20% |
| Combined | 122 | 315 | 38.73% | 36 | 98 | 36.73% | -5.16% | 50 | 135 | 37.04% | 0.84% | 45.00% | 45.10% |
| Use of Imaging Studies for Low Back Pain | | | n=74 | n=78 | | | | n=78 | | | | | |
| | 62 | 74 | 86.78% | 59 | 78 | 75.64% | -12.84% | 58 | 69 | 84.06% | 11.13% | 74.40% | 75.30% |
| DMARD Therapy in Rheumatoid Arthritis | | | n=31 | n=9 | | | | n=17 | | | | | |
| | 30 | 31 | 96.77% | 8 | 9 | 88.89% | -8.14% | 15 | 17 | 88.24% | -0.74% | 87.60% | 87.90% |
| Annual Monitoring for Patients on Persistent Medications | | | n=1066 | n=321 | | | | n=591 | | | | | |
| ACE/ARB | 461 | 581 | 79.35% | 146 | 176 | 82.95% | 4.54% | 286 | 336 | 85.12% | 2.61% | 82.50% | 82.90% |
| Anticonvulsant | 15 | 25 | 60.00% | 5 | 8 | 62.50% | 4.17% | 6 | 8 | 75.00% | 20.00% | 60.50% | 58.80% |
| Digoxin | 15 | 16 | 93.75% | 4 | 4 | 100.00% | 6.67% | 13 | 14 | 92.86% | -7.14% | 85.40% | 86.50% |
| Diuretic | 355 | 444 | 79.95% | 108 | 133 | 81.20% | 1.56% | 198 | 233 | 84.98% | 4.65% | 82.10% | 82.50% |
| Combined | 846 | 1066 | 79.36% | 263 | 321 | 81.93% | 3.24% | 503 | 591 | 85.11% | 3.88% | 81.90% | 82.30% |

* Note: For this numerator, a lower rate indicates better performance.

** Note: The HbA1c < 7.0% denominator excludes members w/ certain conditions. Please see measure description for a list of conditions.

*** Note: The combined age range for this measure changed from 5-50 years in 2011 to 5-64 years in 2012 & 2013.

^The NCQA qualifying dosing requirements for the Hepatitis A immunizations series changed from 2 doses in 2011 & 2012 to 1 dose in 2013.

BCBSMT 2011 rates based on 2010 data.

BCBSMT 2012 rates based on 2011 data.

BCBSMT 2013 rates based on 2012 data.

The 2013QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2013 Report* and reflect 2012 data.

The 2012 QC (Quality Compass®) rate comparisons are from NCQA's *State of Health Care Quality 2012 Report* and reflect 2011 data.